Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK of SY-5007 with Rifampicin or Itraconazole in Healthy Subjects
NCT06332053Phase 1Not yet recruiting
- Sponsor
- Shouyao Holdings
- Start
- Apr 2024
- Primary completion
- Jun 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of sotetinib in non-small cell lung cancer (NSCLC) and solid tumor (2 arms), sponsored by Shouyao Holdings. Primary endpoints: Maximum Plasma Concentration, Time to Maximum Plasma Concentration and 5 more. Planned start Apr 2024; status: not yet recruiting.
02
Drugs
sotetinib
03
Conditions
non-small cell lung cancer (NSCLC)solid tumor
Beyond the preview
Go deeper on NCT06332053.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06332053.